Daehan NupharmLtd（A054670）株式概要大韓ヌファルム株式会社は、医薬品および動物用医薬品を韓国内外で製造・販売している。 詳細A054670 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績3/6財務の健全性3/6配当金1/6報酬株価収益率（ 4.6 x） KR市場（ 11.1 x）を下回っています。過去5年間の収益は年間11.8%増加しました。 リスク分析高いレベルの非現金収入 負債は営業キャッシュフローで十分にカバーされていない 意味のある時価総額がありません ( ₩71B )すべてのリスクチェックを見るA054670 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩5.09k9.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-19b262b2016201920222025202620282031Revenue ₩262.5bEarnings ₩20.0bAdvancedSet Fair ValueView all narrativesDaehan Nupharm Co.,Ltd. 競合他社DK Life ScienceSymbol: KOSDAQ:A303810Market cap: ₩75.3bIldong HoldingsSymbol: KOSE:A000230Market cap: ₩64.5bBIOBIJOULtdSymbol: KOSDAQ:A489460Market cap: ₩88.3bSam-A PharmSymbol: KOSDAQ:A009300Market cap: ₩74.7b価格と性能株価の高値、安値、推移の概要Daehan NupharmLtd過去の株価現在の株価₩5,090.0052週高値₩7,900.0052週安値₩5,050.00ベータ0.151ヶ月の変化-18.17%3ヶ月変化-29.89%1年変化-30.84%3年間の変化-44.91%5年間の変化-55.74%IPOからの変化-33.03%最新ニュースお知らせ • Mar 13Daehan Nupharm Co.,Ltd., Annual General Meeting, Mar 27, 2026Daehan Nupharm Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 66, jeyakgongdan 1-gil, hyangnam-eu, gyeonggi-do, hwaseong South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 20 April 2026. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).分析記事 • Nov 20Solid Earnings May Not Tell The Whole Story For Daehan NupharmLtd (KOSDAQ:054670)Daehan Nupharm Co.,Ltd.'s ( KOSDAQ:054670 ) healthy profit numbers didn't contain any surprises for investors. We...Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: ₩48.9b (flat on 3Q 2024). Net income: ₩2.61b (up 33% from 3Q 2024). Profit margin: 5.3% (up from 4.0% in 3Q 2024).Declared Dividend • Nov 08Dividend of ₩100.00 announcedDividend of ₩100.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 1.6%, which is higher than the industry average of 1.1%. Sustainability & Growth The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years.お知らせ • Nov 07Daehan Nupharm Co.,Ltd. announces Annual dividend, payable on April 20, 2026Daehan Nupharm Co.,Ltd. announced Annual dividend of KRW 100.0000 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.最新情報をもっと見るRecent updatesお知らせ • Mar 13Daehan Nupharm Co.,Ltd., Annual General Meeting, Mar 27, 2026Daehan Nupharm Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 66, jeyakgongdan 1-gil, hyangnam-eu, gyeonggi-do, hwaseong South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 20 April 2026. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).分析記事 • Nov 20Solid Earnings May Not Tell The Whole Story For Daehan NupharmLtd (KOSDAQ:054670)Daehan Nupharm Co.,Ltd.'s ( KOSDAQ:054670 ) healthy profit numbers didn't contain any surprises for investors. We...Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: ₩48.9b (flat on 3Q 2024). Net income: ₩2.61b (up 33% from 3Q 2024). Profit margin: 5.3% (up from 4.0% in 3Q 2024).Declared Dividend • Nov 08Dividend of ₩100.00 announcedDividend of ₩100.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 1.6%, which is higher than the industry average of 1.1%. Sustainability & Growth The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years.お知らせ • Nov 07Daehan Nupharm Co.,Ltd. announces Annual dividend, payable on April 20, 2026Daehan Nupharm Co.,Ltd. announced Annual dividend of KRW 100.0000 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.New Risk • Aug 15New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 8.0% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.0% operating cash flow to total debt). High level of non-cash earnings (31% accrual ratio). Minor Risk Market cap is less than US$100m (₩101.9b market cap, or US$73.5m).お知らせ • Mar 05Daehan New Pharm Co., Ltd., Annual General Meeting, Mar 20, 2025Daehan New Pharm Co., Ltd., Annual General Meeting, Mar 20, 2025, at 09:00 Tokyo Standard Time. Location: seminar room, 66, jeyakgongdan 1-gil, hyangnam-eup, gyeonggi-do, hwaseong South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 15 April 2025. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).Upcoming Dividend • Dec 20Upcoming dividend of ₩100.00 per share at 1.1% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (1.1%).Upcoming Dividend • Dec 21Inaugural dividend of ₩80.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 13 April 2023. This is the first dividend for Daehan New Pharm since going public. The average dividend yield among industry peers is 1.0%.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩8,300, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 19x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 26% over the past three years.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩10,900, the stock trades at a trailing P/E ratio of 6.6x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 13% over the past three years.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.分析記事 • Mar 10Daehan New Pharm Co., Ltd.'s (KOSDAQ:054670) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?Daehan New Pharm (KOSDAQ:054670) has had a rough three months with its share price down 17%. However, a closer look at...Is New 90 Day High Low • Feb 22New 90-day low: ₩11,650The company is down 11% from its price of ₩13,100 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.分析記事 • Feb 17What Type Of Shareholders Own The Most Number of Daehan New Pharm Co., Ltd. (KOSDAQ:054670) Shares?If you want to know who really controls Daehan New Pharm Co., Ltd. ( KOSDAQ:054670 ), then you'll have to look at the...Is New 90 Day High Low • Feb 04New 90-day low: ₩11,700The company is down 2.0% from its price of ₩11,950 on 06 November 2020. The South Korean market is up 27% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period.分析記事 • Jan 21Here's Why Daehan New Pharm (KOSDAQ:054670) Can Manage Its Debt ResponsiblySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Dec 31If You Had Bought Daehan New Pharm's (KOSDAQ:054670) Shares Five Years Ago You Would Be Down 25%Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...分析記事 • Dec 10Is Daehan New Pharm Co., Ltd.'s(KOSDAQ:054670) Recent Stock Performance Tethered To Its Strong Fundamentals?Daehan New Pharm's (KOSDAQ:054670) stock is up by a considerable 7.1% over the past month. Given the company's...Reported Earnings • Nov 16Third quarter 2020 earnings released: ₩82.00 loss per shareThe company reported a soft third quarter result with weaker earnings and control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: ₩39.5b (up 23% from 3Q 2019). Net loss: ₩1.16b (down 137% from profit in 3Q 2019). Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.株主還元A054670KR PharmaceuticalsKR 市場7D-10.2%-6.1%-2.2%1Y-30.8%1.2%171.0%株主還元を見る業界別リターン: A054670過去 1 年間で1.2 % の収益を上げたKR Pharmaceuticals業界を下回りました。リターン対市場: A054670は、過去 1 年間で171 % のリターンを上げたKR市場を下回りました。価格変動Is A054670's price volatile compared to industry and market?A054670 volatilityA054670 Average Weekly Movement4.5%Pharmaceuticals Industry Average Movement6.2%Market Average Movement8.8%10% most volatile stocks in KR Market16.1%10% least volatile stocks in KR Market4.6%安定した株価: A054670 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A054670の 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1984n/aWonseok Leewww.dhnp.co.krLtd.は、医薬品と動物用医薬品を韓国内外で製造・販売している。循環器系、内分泌系、精神神経系、消化器系、呼吸器系、解熱、鎮痛、抗炎症、抗感染症、筋骨格系、骨粗しょう症、抗がん、泌尿生殖器系、抗真菌、抗ウイルス、ホルモン、皮膚科系、中枢神経系、抗けいれん、アミノ酸、麻酔、抗肥満などの医薬品、ビタミン、無機製品を提供。また、動物用健康・栄養製品、健康補助食品、美容・医療機器も提供している。同社は以前は大韓新薬株式会社として知られていたが、2025年3月に大韓ヌファルム株式会社に社名を変更した。1984年に設立され、韓国華城市に本社を置く。もっと見るDaehan Nupharm Co.,Ltd. 基礎のまとめDaehan NupharmLtd の収益と売上を時価総額と比較するとどうか。A054670 基礎統計学時価総額₩71.44b収益（TTM）₩15.68b売上高(TTM)₩205.39b4.6xPER（株価収益率0.3xP/SレシオA054670 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A054670 損益計算書（TTM）収益₩205.39b売上原価₩115.63b売上総利益₩89.76bその他の費用₩74.08b収益₩15.68b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）1.12kグロス・マージン43.70%純利益率7.63%有利子負債／自己資本比率77.2%A054670 の長期的なパフォーマンスは？過去の実績と比較を見る配当金2.0%現在の配当利回りn/a配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/26 17:39終値2026/06/26 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Daehan Nupharm Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 13Daehan Nupharm Co.,Ltd., Annual General Meeting, Mar 27, 2026Daehan Nupharm Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 66, jeyakgongdan 1-gil, hyangnam-eu, gyeonggi-do, hwaseong South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 20 April 2026. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).
分析記事 • Nov 20Solid Earnings May Not Tell The Whole Story For Daehan NupharmLtd (KOSDAQ:054670)Daehan Nupharm Co.,Ltd.'s ( KOSDAQ:054670 ) healthy profit numbers didn't contain any surprises for investors. We...
Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: ₩48.9b (flat on 3Q 2024). Net income: ₩2.61b (up 33% from 3Q 2024). Profit margin: 5.3% (up from 4.0% in 3Q 2024).
Declared Dividend • Nov 08Dividend of ₩100.00 announcedDividend of ₩100.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 1.6%, which is higher than the industry average of 1.1%. Sustainability & Growth The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years.
お知らせ • Nov 07Daehan Nupharm Co.,Ltd. announces Annual dividend, payable on April 20, 2026Daehan Nupharm Co.,Ltd. announced Annual dividend of KRW 100.0000 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
お知らせ • Mar 13Daehan Nupharm Co.,Ltd., Annual General Meeting, Mar 27, 2026Daehan Nupharm Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 66, jeyakgongdan 1-gil, hyangnam-eu, gyeonggi-do, hwaseong South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 20 April 2026. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).
分析記事 • Nov 20Solid Earnings May Not Tell The Whole Story For Daehan NupharmLtd (KOSDAQ:054670)Daehan Nupharm Co.,Ltd.'s ( KOSDAQ:054670 ) healthy profit numbers didn't contain any surprises for investors. We...
Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: ₩48.9b (flat on 3Q 2024). Net income: ₩2.61b (up 33% from 3Q 2024). Profit margin: 5.3% (up from 4.0% in 3Q 2024).
Declared Dividend • Nov 08Dividend of ₩100.00 announcedDividend of ₩100.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 1.6%, which is higher than the industry average of 1.1%. Sustainability & Growth The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years.
お知らせ • Nov 07Daehan Nupharm Co.,Ltd. announces Annual dividend, payable on April 20, 2026Daehan Nupharm Co.,Ltd. announced Annual dividend of KRW 100.0000 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
New Risk • Aug 15New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 8.0% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.0% operating cash flow to total debt). High level of non-cash earnings (31% accrual ratio). Minor Risk Market cap is less than US$100m (₩101.9b market cap, or US$73.5m).
お知らせ • Mar 05Daehan New Pharm Co., Ltd., Annual General Meeting, Mar 20, 2025Daehan New Pharm Co., Ltd., Annual General Meeting, Mar 20, 2025, at 09:00 Tokyo Standard Time. Location: seminar room, 66, jeyakgongdan 1-gil, hyangnam-eup, gyeonggi-do, hwaseong South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 15 April 2025. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).
Upcoming Dividend • Dec 20Upcoming dividend of ₩100.00 per share at 1.1% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (1.1%).
Upcoming Dividend • Dec 21Inaugural dividend of ₩80.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 13 April 2023. This is the first dividend for Daehan New Pharm since going public. The average dividend yield among industry peers is 1.0%.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩8,300, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 19x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 26% over the past three years.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to ₩10,900, the stock trades at a trailing P/E ratio of 6.6x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 13% over the past three years.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
分析記事 • Mar 10Daehan New Pharm Co., Ltd.'s (KOSDAQ:054670) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?Daehan New Pharm (KOSDAQ:054670) has had a rough three months with its share price down 17%. However, a closer look at...
Is New 90 Day High Low • Feb 22New 90-day low: ₩11,650The company is down 11% from its price of ₩13,100 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
分析記事 • Feb 17What Type Of Shareholders Own The Most Number of Daehan New Pharm Co., Ltd. (KOSDAQ:054670) Shares?If you want to know who really controls Daehan New Pharm Co., Ltd. ( KOSDAQ:054670 ), then you'll have to look at the...
Is New 90 Day High Low • Feb 04New 90-day low: ₩11,700The company is down 2.0% from its price of ₩11,950 on 06 November 2020. The South Korean market is up 27% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period.
分析記事 • Jan 21Here's Why Daehan New Pharm (KOSDAQ:054670) Can Manage Its Debt ResponsiblySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Dec 31If You Had Bought Daehan New Pharm's (KOSDAQ:054670) Shares Five Years Ago You Would Be Down 25%Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...
分析記事 • Dec 10Is Daehan New Pharm Co., Ltd.'s(KOSDAQ:054670) Recent Stock Performance Tethered To Its Strong Fundamentals?Daehan New Pharm's (KOSDAQ:054670) stock is up by a considerable 7.1% over the past month. Given the company's...
Reported Earnings • Nov 16Third quarter 2020 earnings released: ₩82.00 loss per shareThe company reported a soft third quarter result with weaker earnings and control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: ₩39.5b (up 23% from 3Q 2019). Net loss: ₩1.16b (down 137% from profit in 3Q 2019). Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
